Clinical Trials Browser

INDUSTRY × polatuzumab vedotin × 1 year × Clear all

NCT05283720 2026-06-02

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Hairy Cell, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06890884 2026-05-29

MK-2140-011

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT03274492 2026-05-08

POLARIX

Phase 3 Completed

1,000 enrolled 1 FDA

Lymphoma, Large B-Cell, Diffuse

NCT05171647 2026-05-07

SUNMO

Phase 3 Active not recruiting

208 enrolled 12 charts

Lymphoma, Non-Hodgkin

NCT05954910 2026-05-01

A Study to Evaluate the Effectiveness and Safety of Polatuzumab in Real World Clinical Practice Among Adult Chinese Participants With Diffuse Large B-Cell Lymphoma

Active not recruiting

Lymphoma, Large B-Cell, Diffuse

NCT04844866 2026-04-29

DALY 2-EU

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Hematologic Neoplasms

NCT04884035 2026-04-17

Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma

Phase 1 Recruiting

Lymphoma, B-Cell

NCT03533283 2026-04-06

An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Phase 1/2 Active not recruiting

Lymphoma, Non-Hodgkin

NCT04970901 2026-03-13

A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

Phase 1 Recruiting

Lymphoma, B-Cell

NCT04182204 2025-12-22

POLARGO

Phase 3 Completed

270 enrolled 36 charts

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT04607772 2025-10-03

Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 1/2 Withdrawn

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT03677154 2025-08-21

Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma

Phase 1/2 Completed

Lymphoma, Large B-Cell, Diffuse